Form 4 for NRIX Nurix Therapeutics, Inc.
Accepted 2025-02-03 00:00:00 ET · period of report 2025-01-31 · accession 0001549595-25-000026 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-02-03 | 2025-01-31 | NRIX | Ring Christine | CLO | M - OptEx | $1.86 | +5,760 | 38.3K | +18% | +$10.7K |
| DM | 2025-02-03 | 2025-01-31 | NRIX | Ring Christine | CLO | S - Sale+OE | $19.95 | -5,760 | 32.6K | -15% | -$114.9K |
| DM | 2025-02-03 | 2025-01-31 | NRIX | Ring Christine | CLO | M - OptEx | $0.00 | -5,760 | 53.8K | -10% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-31 | M | A | 223 | $1.86 | 32,761 | D | — | — | |
| 2 | Common | Common Stock | 2025-01-31 | S | D | 100 | $20.48 | 32,538 | D | — | — | |
| 3 | Common | Common Stock | 2025-01-31 | S | D | 5,660 | $19.94 | 32,638 | D | — | — | (F2) Represents the weighted average sale price. The lowest price at which shares were sold was $19.465 and the highest price at which shares were sold was $20.42. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. |
| 4 | Common | Common Stock | 2025-01-31 | M | A | 5,537 | $1.86 | 38,298 | D | — | — | |
| 5 | Derivative | Employee Stock Option (right to buy) | 2025-01-31 | M | D | 5,537 | $0.00 | 0 | D | $1.86 · — to 2029-11-13 | 5,537 Common Stock | (F3) The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023. |
| 6 | Derivative | Employee Stock Option (right to buy) | 2025-01-31 | M | D | 223 | $0.00 | 53,763 | D | $1.86 · — to 2029-09-30 | 223 Common Stock | (F3) The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023. |